{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:02:56Z","timestamp":1793106176854,"version":"4.5.0"},"reference-count":56,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Beijing Municipal Science and Technology Commission of China","award":["Z191100006619010"],"award-info":[{"award-number":["Z191100006619010"]}],"id":[{"id":"https:\/\/ror.org\/034k14f91","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Beijing Natural science foundation of China","award":["7202219"],"award-info":[{"award-number":["7202219"]}]},{"name":"Research and Development Program of China","award":["2018YFA0902802"],"award-info":[{"award-number":["2018YFA0902802"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802533"],"award-info":[{"award-number":["81802533"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Capital's Funds for Health Improvement and Research of China","award":["2022-4-4087"],"award-info":[{"award-number":["2022-4-4087"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,8,20]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint blockade (ICB) therapy holds promise in metastatic urothelial carcinoma (UC). Fibroblast growth factor receptor 3 (FGFR3) mutation drives T-cell-depleted microenvironment in UC, which led to the hypothesis that FGFR3 mutation might attenuate response to ICB in patients with metastatic UC. The study aims to compare prognosis and response between patients with FGFR3-mutated and FGFR3-wildtype metastatic UC after ICB therapy, and decode the potential molecular mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Based on the single-arm, multicenter, phase 2 trial, IMvigor210, we conducted a propensity score matched (PSM) analysis. After a 1:1 ratio PSM method, 39 patients with FGFR3-mutated and 39 FGFR3-wildtype metastatic UC treated with atezolizumab were enrolled. A meta-analysis through systematical database retrieval was conducted for validation. In addition, we performed single-cell RNA sequencing on three FGFR3-mutated and three FGFR3-wildtype UC tumors and analyzed 58,069 single cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The PSM analysis indicated FGFR3-mutated patients had worse overall survival (OS) in comparison to FGFR3-wildtype patients (HR=2.11, 95% CI=(1.16 to 3.85), p=0.015) receiving atezolizumab. The median OS was 9.2 months (FGFR3-mutated) versus 21.0 months (FGFR3-wildtype). FGFR3-mutated patients had lower disease control rate than FGFR3-wildtype patients (41.0% vs 66.7%, p=0.023). The meta-analysis involving 938 patients with metastatic UC confirmed FGFR3 mutation was associated with worse OS after ICB (HR=1.28, 95% CI=(1.04 to 1.59), p=0.02). Single-cell RNA transcriptome analysis identified FGFR3-mutated UC carried a stronger immunosuppressive microenvironment compared with FGFR3-wildtype UC. FGFR3-mutated UC exhibited less immune infiltration, and lower T-cell cytotoxicity. Higher TREM2+ macrophage abundance in FGFR3-mutated UC can undermine and suppress the T cells, potentially contributing to the formation of an immunosuppressive microenvironment. Lower inflammatory-cancer-associated fibroblasts in FGFR3-mutated UC recruited less chemokines in antitumor immunity but expressed growth factors to promote FGFR3-mutated malignant cell development. FGFR3-mutated UC carried abundance of malignant cells characterized by high hypoxia\/metabolism and low interferon response phenotype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>FGFR3 mutation can attenuate prognosis and response to ICB in patients with metastatic UC. FGFR3-mutated UC carries a stronger immunosuppressive microenvironment in comparison with FGFR3-wildtype UC. Inhibition of FGFR3 might activate the immune microenvironment, and the combination of FGFR inhibitor targeted therapy and ICB might be a promising therapeutic regimen in metastatic UC, providing important implications for UC clinical management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2022-006643","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T06:50:18Z","timestamp":1696056618000},"page":"e006643","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":44,"title":["Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02951767","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02108652","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03473743","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yuxuan","family":"Song","sequence":"first","affiliation":[{"name":"Department of Urology, Peking University People's Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University People's Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caipeng","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University People's Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University People's Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University People's Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University People's Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3899-1500","authenticated-orcid":false,"given":"Tao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University People's Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,9,30]]},"reference":[{"key":"2025100300202192000_11.9.e006643.1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma","volume":"81","author":"Cathomas","year":"2022","journal-title":"Eur Urol"},{"key":"2025100300202192000_11.9.e006643.2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002552","article-title":"Society for Immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer","volume":"9","author":"Galsky","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100300202192000_11.9.e006643.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00152-2"},{"key":"2025100300202192000_11.9.e006643.4","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and Durvalumab plus Tremelimumab versus chemotherapy in previously untreated patients with Unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025100300202192000_11.9.e006643.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30230-0"},{"key":"2025100300202192000_11.9.e006643.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32455-2"},{"key":"2025100300202192000_11.9.e006643.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30616-2"},{"key":"2025100300202192000_11.9.e006643.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683"},{"key":"2025100300202192000_11.9.e006643.9","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre","volume":"391","author":"Powles","year":"2018","journal-title":"The Lancet"},{"key":"2025100300202192000_11.9.e006643.10","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025100300202192000_11.9.e006643.11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0327"},{"key":"2025100300202192000_11.9.e006643.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00561-4"},{"key":"2025100300202192000_11.9.e006643.13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003087","article-title":"Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better","volume":"10","author":"Zheng","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100300202192000_11.9.e006643.14","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1158\/1078-0432.CCR-21-3089","article-title":"Putative biomarkers of clinical benefit with Pembrolizumab in advanced urothelial cancer: results from the KEYNOTE-045 and KEYNOTE-052 landmark trials","volume":"28","author":"Bellmunt","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025100300202192000_11.9.e006643.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.09.006"},{"key":"2025100300202192000_11.9.e006643.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.007"},{"key":"2025100300202192000_11.9.e006643.17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"key":"2025100300202192000_11.9.e006643.18","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501"},{"key":"2025100300202192000_11.9.e006643.19","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-Omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"key":"2025100300202192000_11.9.e006643.20","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.eururo.2017.05.048","article-title":"Comprehensive genomic characterization of upper tract urothelial carcinoma","volume":"72","author":"Moss","year":"2017","journal-title":"Eur Urol"},{"key":"2025100300202192000_11.9.e006643.21","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ccell.2021.05.008","article-title":"Molecular classification and diagnostics of upper urinary tract urothelial carcinoma","volume":"39","author":"Fujii","year":"2021","journal-title":"Cancer Cell"},{"key":"2025100300202192000_11.9.e006643.22","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-33980-9","article-title":"Collaborative study from the bladder cancer advocacy network for the genomic analysis of metastatic urothelial cancer","volume":"13","author":"Damrauer","year":"2022","journal-title":"Nat Commun"},{"key":"2025100300202192000_11.9.e006643.23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.eururo.2022.01.026","article-title":"Comprehensive molecular characterization reveals genomic and transcriptomic subtypes of metastatic urothelial carcinoma","volume":"81","author":"Nakauma-Gonz\u00e1lez","year":"2022","journal-title":"Eur Urol"},{"key":"2025100300202192000_11.9.e006643.24","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.eururo.2019.06.025","article-title":"Fibroblast growth factor receptor 3 alterations and response to PD-1\/PD-L1 blockade in patients with metastatic urothelial cancer","volume":"76","author":"Wang","year":"2019","journal-title":"Eur Urol"},{"key":"2025100300202192000_11.9.e006643.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323"},{"key":"2025100300202192000_11.9.e006643.26","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-020-02230-w","article-title":"Comprehensive integrative profiling of upper tract urothelial carcinomas","volume":"22","author":"Su","year":"2021","journal-title":"Genome Biol"},{"key":"2025100300202192000_11.9.e006643.27","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0274"},{"key":"2025100300202192000_11.9.e006643.28","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10873-y","article-title":"Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling","volume":"10","author":"Robinson","year":"2019","journal-title":"Nat Commun"},{"key":"2025100300202192000_11.9.e006643.29","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-2362"},{"key":"2025100300202192000_11.9.e006643.30","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.euo.2020.04.005","article-title":"Can patients with muscle-invasive bladder cancer and fibroblast growth factor Receptor-3 alterations still be considered for Neoadjuvant Pembrolizumab? A comprehensive assessment from the updated results of the PURE-01 study","volume":"4","author":"Necchi","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"2025100300202192000_11.9.e006643.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01488-6"},{"key":"2025100300202192000_11.9.e006643.32","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6004"},{"key":"2025100300202192000_11.9.e006643.33","doi-asserted-by":"crossref","unstructured":"Chakravarty D , Gao J , Phillips SM , et al . OncoKB: a precision oncology knowledge base. JCO Precis Oncol 2017;2017. doi:10.1200\/PO.17.00011","DOI":"10.1200\/PO.17.00011"},{"key":"2025100300202192000_11.9.e006643.34","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"2025100300202192000_11.9.e006643.35","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1158\/1078-0432.CCR-22-0200","article-title":"Clinico-Genomic characterization of patients with metastatic urothelial carcinoma in real-world practice identifies a novel bladder immune performance index","volume":"28","author":"Szabados","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025100300202192000_11.9.e006643.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8"},{"key":"2025100300202192000_11.9.e006643.37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.urology.2021.05.055","article-title":"Prognostic role of FGFR alterations and FGFR mRNA expression in metastatic urothelial cancer undergoing checkpoint inhibitor therapy","volume":"157","author":"Tully","year":"2021","journal-title":"Urology"},{"key":"2025100300202192000_11.9.e006643.38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clgc.2022.11.007","article-title":"Genomic and clinical prognostic factors in patients with advanced urothelial carcinoma receiving immune checkpoint inhibitors","volume":"21","author":"Chawla","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"2025100300202192000_11.9.e006643.39","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELL.2020.05.017"},{"key":"2025100300202192000_11.9.e006643.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.07.013"},{"key":"2025100300202192000_11.9.e006643.41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18916-5"},{"key":"2025100300202192000_11.9.e006643.42","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2020.07.002","article-title":"FGFR3 mutation status and FGFR3 expression in a large bladder cancer cohort treated by radical cystectomy: implications for anti-FGFR3 treatment?","volume":"78","author":"van Rhijn","year":"2020","journal-title":"Eur Urol"},{"key":"2025100300202192000_11.9.e006643.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.06.013"},{"key":"2025100300202192000_11.9.e006643.44","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.eururo.2020.07.018","article-title":"Fibroblast growth factor receptor 3 alteration status is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothelial carcinoma","volume":"78","author":"Teo","year":"2020","journal-title":"Eur Urol"},{"key":"2025100300202192000_11.9.e006643.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.01.032"},{"key":"2025100300202192000_11.9.e006643.46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01140"},{"key":"2025100300202192000_11.9.e006643.47","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.eururo.2020.08.002","article-title":"Hyperphosphatemia secondary to the selective fibroblast growth factor receptor 1-3 inhibitor Infigratinib (BGJ398) is associated with antitumor efficacy in fibroblast growth factor receptor 3-altered advanced\/metastatic urothelial carcinoma","volume":"78","author":"Lyou","year":"2020","journal-title":"Eur Urol"},{"key":"2025100300202192000_11.9.e006643.48","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002850","article-title":"Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events","volume":"9","author":"Siddiqui","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100300202192000_11.9.e006643.49","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.eururo.2022.01.028","article-title":"Adverse events of immune checkpoint inhibitors therapy for urologic cancer patients in clinical trials: a collaborative systematic review and meta-analysis","volume":"81","author":"Wu","year":"2022","journal-title":"Eur Urol"},{"key":"2025100300202192000_11.9.e006643.50","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003965","article-title":"Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis","volume":"10","author":"Kawai","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100300202192000_11.9.e006643.51","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.08.2103","article-title":"LBA27 Erdafitinib (ERDA) or ERDA plus Cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations","volume":"32","author":"Powles","year":"2021","journal-title":"Ann Oncol"},{"key":"2025100300202192000_11.9.e006643.52","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0235-4"},{"key":"2025100300202192000_11.9.e006643.53","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202205613","article-title":"ETV4 mediated tumor-associated neutrophil infiltration facilitates lymphangiogenesis and lymphatic metastasis of bladder cancer","volume":"10","author":"Zhang","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"2025100300202192000_11.9.e006643.54","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/cac2.12284","article-title":"HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5\u2010WDR5\u2010Dependent transcriptional program","volume":"42","author":"Huang","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"2025100300202192000_11.9.e006643.55","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s13046-021-01989-5","article-title":"Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"2025100300202192000_11.9.e006643.56","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-006643","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T07:20:34Z","timestamp":1759476034000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-006643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":56,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,30]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/jitc-2022-006643"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-006643","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}